NCT04177004 2026-04-15
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
City of Hope Medical Center
Phase 1 Suspended
Clinical Trials
181 trialsNCT06077500 2026-04-14
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT03220022 2026-04-13
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04301076 2026-04-13
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05595460 2026-04-13
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
RayzeBio, Inc.
Phase 1 Active not recruiting
NCT04560972 2026-04-07
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05815160 2026-03-30
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Debiopharm International SA
Phase 1 Active not recruiting
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04231877 2026-03-03
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
Phase 1 Recruiting
NCT05361395 2026-03-03
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Phase 1 Active not recruiting
NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
NCT07381829 2026-02-02
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
HC Biopharma Inc.
Phase 1 Recruiting
NCT01959698 2026-01-28
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT05762419 2026-01-28
FUS Etoposide for DMG
Columbia University
Phase 1 Recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT06132113 2025-12-17
DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
Phase 1 Recruiting
NCT01840566 2025-12-03
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05364424 2025-12-01
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
NCT02964013 2025-10-14
KEYVIBE-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05270057 2025-10-09
LONCA
Medical College of Wisconsin
Phase 1 Active not recruiting
NCT02153580 2025-10-06
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04631029 2025-10-03
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
Phase 1 Completed
NCT04047862 2025-08-22
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT07009457 2025-07-04
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT03567642 2025-07-03
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06719973 2025-06-17
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
EMD Serono
Phase 1 Withdrawn
NCT00641381 2025-05-01
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04870112 2025-04-17
SCope-D1
AstraZeneca
Phase 1 Terminated
NCT02632708 2025-04-11
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Active not recruiting
NCT01476839 2025-03-20
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT02342782 2025-03-20
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT06732258 2024-12-27
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Not yet recruiting
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT04521946 2024-10-26
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02815592 2024-09-04
Trial of BMS-986012 in Combination With Platinum and Etoposide
Bristol-Myers Squibb
Phase 1 Completed
NCT03850067 2024-08-26
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT01059071 2024-08-06
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Phase 1 Completed
NCT00881166 2024-08-02
SGI-0470-02
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT01798004 2024-07-15
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05116007 2024-05-31
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Akeso
Phase 1 Completed
NCT03864419 2024-01-03
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT00968760 2023-12-19
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06164327 2023-12-11
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 1 Unknown